The technology platform that Selecta Biosciences Inc. hopes will create new vaccines combines biodegradable polymers, formulated as nanoparticles, that can be processed in such a way that they “self-assemble” along with antigens and synthetic elements into complexes able to evoke clinically relevant immune responses. Selecta says its nanoparticles stimulate a human immune response similar to that roused by naturally occurring pathogens, perhaps because they are similar in size to a virus and because antigen is arrayed on the outside to optimally interact with the body’s B cells. On the inside, the nanoparticles contain what Selecta considers a “proprietary and universal” T-cell antigen intended to elicit a strong memory T-cell response. The interior of the company’s nanoparticles also contain a TLR, or Toll-like receptor, agonist meant to act as an adjuvant.
480 Arsenal Street
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
The Belgian drugmaker is boosting its biologics capacity over the pond.
Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?
The French company will start shipping its blockbuster shortly to meet expected strong demand in the 2025–26 RSV season.
Oral RNA splicing modulator has gone into a Phase II/III trial
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.
Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.
